OR WAIT null SECS
Check out the latest features and columns!
Supply chain issues, psychedelic medicines, immunotherapies, social engagement, telemedicine, access barriers, corporate branding, and the rise of Chinese biotech are industry topics that deserve a closer look as we head into the future
January's Executive Profile features CEO of Sumitovant Biopharma, Myrtle Potter
Pharm Exec's 17th Annual Pipeline Report focuses on Alzheimer’s disease, ophthalmology, NASH, anti-infectives, and opioids
These five brands prove that pharma marketers can pull it together with compelling stories, and meaningful patient impact, even during a pandemic
Chief commercial officers gather for an insightful roundtable discussion anchored in the future of sales and marketing in light of new communication media brought on by the pandemic
How can clinical trials be designed to best study therapies for treating long COVID?
Highlighted Videos
January 12, 2022
In a highly unusual decision for a therapy approved by FDA, CMS has taken action to limit prescribing and use of Biogen’s new and controversial Alzheimer’s treatment Aduhelm.
January 11, 2022
Industry experts convene for discussion on new quality management systems.
Government-led programs aim to attract scientists and offer resources to growing industry.
Pharma moves beyond promoting products to increase recognition of company names.
Employer-sponsored health plans create an increasingly cloudy path to access.
Standard for reaching patients shifts with influx of new technology in post-COVID world.
Pandemic lockdowns push pharma into brand-new era of social engagement.
Oncology and rare disease are ready to reap the benefits of COVID drug development.
Growing evidence supports psychoactive substances can successfully treat mental issues.
As borders shut down during the pandemic, pharma learned some lessons about sourcing.
